Bensarazid with L dopa in the treatment of Parkinson's disease
A short review is given of the pharmacokinetics and pharmacodynamics of the decarboxylase inhibitor Ro 4-4602. The results obtained in 20 patients using this drug in combination with L dopa, are described. Reduction in the total dosage of L dopa by 1/6 to 1/10 the single preparation gave marked relief of nausea. The induction period of the dosage was smoother, and an optimum dose could be reached sooner with earlier signs of improvement in comparison with the single drug.